Tufts Medical Center

MNA Nurses Call Brigham and Women's Hospital's Lax Visitor Policy Unsafe During Omicron COVID Surge; Nurses Worry Hospital is Super Spreader

Retrieved on: 
Tuesday, January 11, 2022
Nursing, Patient, BWH, Policy, Tufts University, Boston Medical Center, Legislature, COVID-19, St. Elizabeth Medical Center, Safety, Workplace, Medical Center, Lahey Hospital & Medical Center, Health, PPE, Time, N95 respirator, Caregiver, Brigham and Women's Hospital, Skype, Association, Education, Hospital, Multimedia, Risk, Commonwealth, Infection, Tufts Medical Center, Friends, FaceTime, Omicron, COVID, Medicine, Brigham, N95

With so many caregivers out with COVID, we would hope hospital executives would step up their efforts to protect us."

Key Points: 
  • With so many caregivers out with COVID, we would hope hospital executives would step up their efforts to protect us."
  • Brigham nurses have been urging the hospital to improve its response to the current COVID surge, but management is not listening.
  • When nurses look at the lax visitor policy, PPE issues and lack of booster and testing availability, they see the Brigham as practically an ongoing super spreader event.
  • Founded in 1903, the Massachusetts Nurses Association is the largest union of registered nurses in the Commonwealth of Massachusetts.

Global Community Oncology Services Market Report 2021: Market to Decline to 2025 Due to COVIID-19 - Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 7, 2022
Health, Oncology, Community Oncology Alliance, Pharmacy technician, McKesson Corporation, COVID-19, Acquisition, CCS, Growth, Health, Nursing, Pharmacist, Patient, Organization, TRIO, Neoplasm, Hospital, Tufts Medical Center, Doctors Medical Center San Pablo Campus, Physician, Amgen, HCS, Animal, Medicine, Medical imaging, Oil, Coronavirus

The "Community Oncology Services Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Community Oncology Services Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The community oncology services market consists of sales of community oncology services by entities (organizations, sole traders and partnerships) of health practitioners who practice community oncology as a private physician-owned business not part of a hospital or academic or medical teaching institution.
  • The coronavirus outbreak has caused a rapid decline in overall oncology in-person services, subsequently impacting the community oncology services market.
  • Hence, the low cost of community oncology settings or community oncology centers is expected to drive the demand for the community oncology services market over the forecast years.

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

Retrieved on: 
Wednesday, December 15, 2021
Forward-looking statement, Therapy, U.S. Securities and Exchange Commission, PVR, Form, Heart failure, Constriction, Clinical trial, Pulmonary circulation, Volunteering, Adult, Growth, Private Securities Litigation Reform Act, Nasdaq, COVID-19, Critical care, Pulmonary hypertension, SEC, Aerovent, Life expectancy, Tufts Medical Center, Safety, Goal, Patient, Disease, Security (finance), Hypertensive emergency, GLOBE, Trial of the century, Heart, Pharmaceutical industry, Risk management

We are excited and humbled to initiate this Phase 2b/Phase 3 trial of AV-101, said Tim Noyes, Chief Executive Officer at Aerovate.

Key Points: 
  • We are excited and humbled to initiate this Phase 2b/Phase 3 trial of AV-101, said Tim Noyes, Chief Executive Officer at Aerovate.
  • Starting enrollment represents an important milestone for Aerovate Therapeutics and advances our goal of improving the lives of patients suffering from rare cardiovascular diseases.
  • Aerovate expects to report top-line results from the Phase 2b portion of IMPAHCT in mid-2023.
  • IMPAHCT is a multi-national, placebo-controlled Phase 2b/Phase 3 trial in adults with pulmonary arterial hypertension (PAH) that will continuously enroll patients as the study progresses from Phase 2b to Phase 3.

OKYO Pharma Limited ("OKYO" or the "Company") Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

Retrieved on: 
Monday, December 13, 2021
Computer, LSE, Research, Immunology, Company, American Academy of Ophthalmology, DED, Population, MAP, Copy, American Academy, Duane syndrome, Industry, Association for Research in Vision and Ophthalmology, Official List, London Stock Exchange Group, UK, Association, Biotechnology, Tufts Medical Center, London Stock Exchange, Patient, Molecule, Department, Eye, Financial Conduct Authority, Interim, Ageing, Editing, Technology, Pharmaceutical industry, Medicine, Ophthalmology

Dr. Hamrah is a Interim Chair of the Department of Ophthalmolgy at Tufts Medical Center, a clinician/scientist and prominent KOL in the field of dry eye disease, ocular pain, and ocular immunology.

Key Points: 
  • Dr. Hamrah is a Interim Chair of the Department of Ophthalmolgy at Tufts Medical Center, a clinician/scientist and prominent KOL in the field of dry eye disease, ocular pain, and ocular immunology.
  • OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain.
  • Dry eye is a multifactorial disease that results in ocular discomfort and tear film instability that can lead to ocular surface damage.
  • Novel therapies that improve the signs and symptoms of dry eye disease will be beneficial to dry eye patients.

MNA Nurse to Testify about the Impact of Unsafe Staffing on Patient Care and the Nursing Workforce During Future of Work Commission Hearing on December 17

Retrieved on: 
Thursday, December 16, 2021
Hospital, COVID, Workforce, Workforce development, Workplace, MNA, Morale, Health, Friends, Center, Industry, Descriptive ethics, Working Commission to Investigate the Use of Psychiatry for Political Purposes, COVID-19, Time, Massachusetts General Court, Family, Moral injury, Association, Tufts Medical Center, Workload, Patient, Commonwealth, Multimedia, Legislature, Legislation, Injury, Infection, Future, Acceleration, Approximation error, OR, 2019–2020 Massachusetts legislature, Medicine, Nursing

Charlie Baker in January 2021, is studying the impact of new workforce developments on workers, employers, and the economy.

Key Points: 
  • Charlie Baker in January 2021, is studying the impact of new workforce developments on workers, employers, and the economy.
  • Morale is low, burnout is high, and many nurses are walking away from the bedside with no plan to return.
  • It absolutely fails nurses who are trying to fulfill our professional and moral obligations to provide safe, high-quality patient care."
  • The nursing workforce crisis is having a direct impact on the quality of patient care in Massachusetts.

CereVasc Announces Publication of First-in-Human Case Report of its eShunt System for the Treatment of Communicating Hydrocephalus

Retrieved on: 
Tuesday, December 7, 2021
Risk, Hydrocephalus, Neuroradiology, Hospital, CSF, Failure, CH, Patient, CEO, Journal, Clinica 0-19, Multimedia, Clinical trial, Tufts Medical Center, Sudarshan K. Aggarwal, Sale, Infection, Journal of NeuroInterventional Surgery, Lists of diseases, Pharmaceutical industry, Medical device

BOSTON, Dec. 7, 2021 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today the publication of a case report detailing the first treatment in a study of its eShuntâ System, an investigational device intended to treat communicating hydrocephalus (CH), one of the most common neurological conditions worldwide. Representing the first minimally invasive treatment for CH, the eShunt device offers the potential to result in significant benefits over current treatment, a half-century old neurosurgical procedure associated with frequent failure, infection risk and high costs.

Key Points: 
  • The publication, titled, "First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt," can be accessed through this link .
  • The details and outcome of this case are encouraging signs about the potential of the eShunt System to address a common neurological condition with a long history of poor treatment options."
  • The ongoing first-in-human clinical trial, ETCHES I (Endovascular Treatment of Communicating Hydrocephalus with the eShunt System), is evaluating the investigational device for the treatment of communicating hydrocephalus.
  • It's flagship product, the eShuntSystem, is intended to offer the first minimally invasive treatment for communicating hydrocephalus (CH) and an improvement to the current standard of care.

MNA Nurse to Testify about the Impact of Unsafe Staffing on Patient Care and the Nursing Workforce During Future of Work Commission Hearing on December 6

Retrieved on: 
Monday, December 6, 2021
Patient, Massachusetts General Court, Workload, Workforce, Industry, Time, Workforce development, Hospital, Commonwealth, OR, MNA, Legislature, COVID-19, Legislation, Family, Workplace, 2019–2020 Massachusetts legislature, Center, Morale, Approximation error, Health, Infection, Acceleration, Moral injury, Friends, Tufts Medical Center, Descriptive ethics, Multimedia, Association, Injury, Future, Working Commission to Investigate the Use of Psychiatry for Political Purposes, COVID, Medicine

Charlie Baker in January 2021, is studying the impact of new workforce developments on workers, employers, and the economy.

Key Points: 
  • Charlie Baker in January 2021, is studying the impact of new workforce developments on workers, employers, and the economy.
  • Morale is low, burnout is high, and many nurses are walking away from the bedside with no plan to return.
  • It absolutely fails nurses who are trying to fulfill our professional and moral obligations to provide safe, high-quality patient care."
  • The nursing workforce crisis is having a direct impact on the quality of patient care in Massachusetts.

Laudio Announces Client Expansions With Novant Health, Tufts Medical Center and UNC Health to Support Frontline Leaders and Teams

Retrieved on: 
Tuesday, November 30, 2021
Technology, Nursing, Human Resources, Hospitals, Professional Services, Software, Practice Management, Health, Data Management, Floros, Senior, Health, Principal, Pressure, Industry, Chief executive officer, Hospital, UNC, Novant Health, COO, Solution, COVID-19, Goal, National Vanguard (American organization), Â, Efficiency, Tufts Medical Center, UNC Health Care, UNC Medical Center, COVID, Risk management, Management, Medicine

Laudio, an intelligent leadership solution for todays healthcare leaders, announces important expansions with three major clients - Novant Health, Tufts Medical Center and UNC Health.

Key Points: 
  • Laudio, an intelligent leadership solution for todays healthcare leaders, announces important expansions with three major clients - Novant Health, Tufts Medical Center and UNC Health.
  • With COVID pandemic placing unprecedented pressure on todays health systems, frontline leaders are facing a new economy where staffing turnover and stress levels are at their highest.
  • Tufts MC recently expanded with Laudio to leverage the platforms capabilities to better coordinate the facilitation of patient rounds across the health system.
  • Today, forward-thinking leaders across health systems all use Laudio to scale their impact while leaving the workday more satisfied.

MedExecWomen Empowers Women in Leadership Roles in the Medical Device Diagnostics and Digital Health Industries

Retrieved on: 
Tuesday, November 9, 2021
Medical Devices, Health, Consumer, Women, General Health, Biotechnology, Female, Leadership, Tufts Medical Center, Health, Boston Scientific, GE Healthcare, CEO, UnitedHealth Group, COVID, Bill & Melinda Gates Foundation, Mass General Brigham, Medtronic, Woman, Johnson & Johnson, Physician, Bill, Pharmaceutical industry, Management

MedExecWomen , an organization dedicated to empowering women in leadership roles in the medical device, diagnostics, drug delivery, and digital healthcare industries, hosted the second annual MedExecWomen conference on October 26, 2021, in Boston, MA.

Key Points: 
  • MedExecWomen , an organization dedicated to empowering women in leadership roles in the medical device, diagnostics, drug delivery, and digital healthcare industries, hosted the second annual MedExecWomen conference on October 26, 2021, in Boston, MA.
  • MedExecWomen does just this sharing learnings and building networks with peers that will drive further improvements in outcomes.
  • Maria Shepherd of Medi-Vantage said, We had an amazing turnout with over one hundred women attending the MedExecWomen meeting.
  • MedExecWomen is dedicated to empowering women in leadership roles in the medical device, diagnostics, drug delivery, and digital healthcare industries by arming female executives with relevant skills and robust networks.

PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development

Retrieved on: 
Monday, November 8, 2021
DMD, Tufts Medical Center, Biogen, DMPK, Edos, Pharmacology, Multiple sclerosis, Senior, Degenerative disease, EDO, Duchenne muscular dystrophy, Central Drug Research Institute, Twitter, DM1, Doctor of Philosophy, Toxicology, GLOBE, LinkedIn, Solution, OSI, Patient, MS, Clinical Science (journal), Pharmaceutical industry

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc. ,a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the addition of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development.

Key Points: 
  • BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc. ,a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the addition of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development.
  • Most recently, she served as Senior Vice President of Preclinical and Clinical Sciences at Wave Life Sciences, and also spent over 20 years in roles of increasing responsibility at Biogen.
  • Jaya Goyal, Ph.D. brings nearly 30 years of experience in research and development to PepGen.
  • The company is headquartered in Boston, Mass.For more information, visit www.pepgen.com or follow PepGen on Twitter and LinkedIn .